MELANOMA DRUG RESIST
Identification of drug-resistance genes for the development of effective combined therapies for melanoma
| Coordinatore | GENOME RESEARCH LIMITED
Organization address
address: THE GIBBS BUILDING, EUSTON ROAD 215 contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 221˙606 € |
| EC contributo | 221˙606 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2013-IEF |
| Funding Scheme | MC-IEF |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-07-01 - 2016-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
GENOME RESEARCH LIMITED
Organization address
address: THE GIBBS BUILDING, EUSTON ROAD 215 contact info |
UK (LONDON) | coordinator | 221˙606.40 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Malignant melanoma is a highly aggressive form of skin cancer with a poor outcome following metastatic spread. Chemotherapies for metastatic melanoma are rarely curative because of the emergence of clones from within the tumor that carry lesions in genes that confer therapeutic resistance. Understanding the genetic culprits of drug resistance will allow the rationale development of combination therapies that may circumvent the occurrence of resistance. Here I propose to combine different cutting-edge technologies and functional screenings in human early-passage melanoma cell cultures (EMCCs) to identify clinically relevant melanoma drug-resistance genes and consequently to develop new effective combination therapies by a data-driven approach. I will screen a library of drugs across a collection of EMCCs and in concert analyze the genome of each EMCC for mutations, epimutations and chromosomal aberrations. EMCCs found to be intrinsically resistant to a given drug will be screened with a short-hairpin-RNA library to identify genes whose knockdown reverts resistance. Those EMCCs sensitive to a given drug will be infected with lentiviral-vector based insertional mutagens to screen for genes whose upregulation mediates drug resistance, thus identifying mechanisms that may be associated with relapse in patients treated with these compounds. These 2 approaches will provide a collection of drug-resistance and -sensitivity genes that will be then validated in vitro, in vivo and in clinical samples. The knowledge of drug-resistance genes and genomic lesions carried by each EMCC will guide the design of new therapies based on the combination of multiple compounds targeting both the mutated gene and the EMCC-specific drug-resistance gene. The new combination regimens will be tested in vitro on EMCCs and in vivo in xenotransplant models. These results will pave the way to preclinical and clinical development of new combined therapies for the efficient eradication of melanoma.'